HOUSTON, March 9, 2022 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the
"Company"), a biopharmaceutical company specializing in the
development of novel treatments for primary and metastatic cancers
in the brain and central nervous system, today released a video to
shareholders reiterating its operational and clinical progress for
lead product candidate, Berubicin, and addressing recent share
price activity.
"The divergence that exists between our operational strength and
share price is top of mind for myself and the whole team at CNS
Pharmaceuticals. As a shareholder of CNS Pharma, I share in the
frustrations as it pertains to the share price and fluctuation in
the market – both of which are things out of our control. However,
as the CEO, what I do have control over is executing on the
day-to-day operations, which I want to reiterate and emphasize,
have simply never been stronger. We continue to enroll patients
around the world in our potentially pivotal study of Berubicin in
the treatment of adult GBM. We have the leading minds in the field
around the world working on this trial with us and we have
encouraging ongoing dialogue with the FDA to ensure that our
potentially pivotal trial continues to represent the
state-of-the-art in the field. So, while what we cannot control
remains to be a point of frustration, we are committed to
continuing to execute our operational excellence to drive
recognition in the market of Berubicin and what we believe could be
its immense potential for patients – the key driver for ultimately
generating shareholder value and tremendous hope for GBM patients
worldwide," commented John Climaco,
CEO of CNS Pharmaceuticals. "We put our heads down every day and
continue to charge forward in our mission to change the game in
glioblastoma via Berubicin."
Berubicin is a novel anthracycline and the first anthracycline
to appear to cross the blood-brain barrier. Berubicin is currently
in development for the treatment of a number of serious brain and
CNS oncology indications. Patient enrollment, randomization and
dosing is currently underway, and the Company has a robust lineup
of clinical sites located globally which are advancing toward
activation and enrollment.
For more information about the ongoing potentially pivotal
Berubicin trial, visit clinicaltrials.gov and reference identifier
NCT04762069.
To access the video, please visit the Company's website.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244/WP1874 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the
treatment of other primary brain and central nervous system
cancers, as well as cancers metastatic to the brain including
pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, CNS's ability to continue to
recruit patients for its potentially pivotal study to evaluate
efficacy of Berubicin in the treatment of adult GBM; and CNS's
ability to complete enrollment in the potentially pivotal clinical
trial for GBM. These statements relate to future events, future
expectations, plans and prospects. Although CNS believes the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-reiterates-operational-progress-and-addresses-recent-share-price-activity-in-video-to-shareholders-301498585.html
SOURCE CNS Pharmaceuticals, Inc.